ArticleJournal of hematology & oncology2011
High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma.
Article in Journal of hematology & oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 75 citations in OpenAlex.
- Evaluation of Signal Transducer and Activator of Transcription 3 (STAT-3) Protein Expression in Non-Hodgkin Lymphoma Cases in Hospital USM.Diagnostics (Basel, Switzerland) · 2023Article
- The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells.Diagnostics (Basel, Switzerland) · 2022Review
- Review
- RNAscope dual ISH-IHC technology to study angiogenesis in diffuse large B-cell lymphomas.Histochemistry and cell biology · 2020Article
- Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients.Journal of Cancer · 2020Article
- Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma.Cancer science · 2019Article
- Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.Journal of hematopathology · 2019Article
- JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type.Oncology reports · 2019Article
- STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma.Translational oncology · 2019Article
- Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.Journal of translational medicine · 2018Article
- Loss of TNFAIP3 enhances MYD88Blood cancer journal · 2018Article
- Mutations in the signal transducer and activator of transcription family of genes in cancer.Cancer science · 2018Review
- STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.Journal of veterinary internal medicine · 2018Article
- Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.Oncotarget · 2017Article
- Over-expression of Activated Signal Transducer and Activator of Transcription 3 Predicts Poor Prognosis in Upper Tract Urothelial Carcinoma.International journal of medical sciences · 2017Article
- Review
- Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.Blood cancer journal · 2016Article
- BCL3 exerts an oncogenic function by regulating STAT3 in human cervical cancer.OncoTargets and therapy · 2016Article
- Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.Oncotarget · 2015Article
- Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.Molecular cancer · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of the study was to investigate the expression and prognostic value of STAT3 in diffuse large B-cell lymphoma (DLBCL).
methodsSeventy-four DLBCL patients from 2001 to 2007 were reviewed in the study. The STAT3 expression in their tumor tissues was examined using the immunohistochemistry (IHC) method, and evaluated for its association with clinicopathological parameters.
resultsStrong nuclear staining of STAT3 and phosphorylated-STAT3tyr705 (P-STAT3) were observed in 19 cases (25.7%) and 24 cases (32.4%), respectively, and the expression levels were highly consistent between them (P = 0.001). The high nuclear expression of STAT3 was more frequent in the non-germinal center B cell-like (non-GCB) DLBCL than that in the GCB subtype, but not reaching significance (P < 0.061). The high nuclear expression of STAT3 was found to be correlated with poor overall survival (OS) (P = 0.005). Multivariate Cox regression analysis showed that the STAT3 expression was an independent prognostic factor for DLBCL patients regardless of CHOP or R-CHOP regimen used as the first-line therapy.
conclusionSTAT3 is more frequently expressed in non-GCB DLBCL than that in GCB subtype, and its strong nuclear expression is correlated with poor OS in DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.